首页> 美国卫生研究院文献>BMJ Open Access >Extended report: Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised double-blind placebo-controlled GO-AFTER study through week 160

【2h】

Extended report: Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised double-blind placebo-controlled GO-AFTER study through week 160

机译：扩展报告：戈利木单抗用于先前有肿瘤坏死因子抑制剂治疗经验的活动性类风湿关节炎患者：一项随机双盲安慰剂对照GO-AFTER研究长期延长至160周的结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

ObjectiveThe aim of this study was to assess long-term golimumab therapy in patients with rheumatoid arthritis (RA) who discontinued previous tumour necrosis factor alpha (TNFα) inhibitor(s) for any reason.

机译：目的这项研究的目的是评估由于任何原因停用先前的肿瘤坏死因子α（TNFα）抑制剂的类风湿关节炎（RA）患者的长期golimumab治疗。

著录项

期刊名称 BMJ Open Access
作者
Josef S Smolen; Jonathan Kay; Robert B M Landewé; Eric L Matteson; Norman Gaylis; Jurgen Wollenhaupt; Frederick T Murphy; Yiying Zhou; Elizabeth C Hsia; Mittie K Doyle;
展开▼
作者单位

展开▼
年(卷),期 -1(71),10
年度 -1
页码 1671–1679
总页数 9
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: Results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160 [J] . SmolenJ.S., KayJ., LandewéR.B.M., Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2012,第10期

机译：曾有肿瘤坏死因子抑制剂治疗经验的活动性类风湿关节炎患者的戈利木单抗：随机，双盲，安慰剂对照GO-AFTER研究长期延长至160周的结果
2. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. [J] . Smolen JS, Kay J, Doyle MK The Lancet . 2009,第9685期

机译：使用肿瘤坏死因子α抑制剂治疗的活动性类风湿关节炎患者的戈利木单抗（GO-AFTER研究）：一项多中心，随机，双盲，安慰剂对照的III期临床试验。
3. Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study [J] . Josef S Smolen, Jonathan Kay, Mittie Doyle, Arthritis Research . 2015,第1期

机译：用肿瘤坏死因子α抑制剂治疗后活动性类风湿关节炎患者的戈利木单抗：在多中心，随机，双盲，安慰剂对照，3期GO-AFTER研究中长达五年的治疗结果
4. Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter randomized double-blind placebo-controlled phase 3 GO-AFTER study [O] . Josef S Smolen, Jonathan Kay, Mittie Doyle, 2015

机译：用肿瘤坏死因子α抑制剂治疗后活动性类风湿关节炎患者的戈利木单抗：多中心随机双盲安慰剂对照3期GO-AFTER研究中长达五年的治疗结果
5. Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160 [O] . Smolen, Josef S., Kay, Jonathan, Landewé, Robert B. M., 2012

机译：曾有肿瘤坏死因子抑制剂治疗经验的活动性类风湿关节炎患者的戈利木单抗：随机，双盲，安慰剂对照GO-AFTER研究长期延长至160周的结果

Extended report: Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised double-blind placebo-controlled GO-AFTER study through week 160

摘要

著录项

相似文献

相关主题

期刊订阅